Clinical trials in CNS--SMi's eighth annual conference.
The SMi's Eighth Annual Conference on Clinical Trials in CNS, held in London, included topics covering new therapeutic developments in the field of CNS disorders. This conference report highlights selected presentations on emerging clinical targets for the treatment of Alzheimer's disease, achievements of the Alzheimer's Disease Neuroimaging Initiative, computational assessment methods applicable to Alzheimer's disease and to the monitoring of suicidality, the accelerated antidepressive effect of PNB-01 (PharmaNeuroBoost NV; comprising a combination of pipamperone and citalopram), and clinical trials in amyotrophic lateral sclerosis and spinal muscular atrophy. Investigational drugs discussed also include begacestat (Pfizer Inc) and olesoxime (Trophos SA).
Kirk
Rebecca
R
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. rebecca.kirk@thomsonreuters.com
D000818:Animals; D002491:Central Nervous System Agents / Q000494:pharmacology*; D002493:Central Nervous System Diseases / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D015195:Drug Design; D015507:Drugs, Investigational / Q000494:pharmacology*; D006801:Humans
D002491:Central Nervous System Agents; D015507:Drugs, Investigational